Medicare’s GLP-1 Drug Pricing Overhaul: A High-Stakes Gamble for Patients, Pharma, and Public Health

Executive Summary

The Biden administration’s landmark pricing policy for glucagon-like peptide-1 receptor agonists (GLP-1RAs) marks a seismic shift in U.S. drug pricing, targeting medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Set to launch in November 2025, the 'Most Favored Nation' (MFN) framework ties Medicare’s reimbursement rates to the lowest prices paid in Canada, Germany, France, Japan, or the UK. Proponents argue the policy could expand access to life-saving treatments for diabetes and obesity, while critics warn of potential shortages, financial instability for Medicare, and unintended consequences for pharmaceutical innovation. This report examines the policy’s implications for patients, healthcare systems, and the broader public health landscape, offering actionable guidance for stakeholders navigating this uncharted territory.

What Happened

The White House has finalized a sweeping pricing overhaul for GLP-1 receptor agonists (GLP-1RAs), a class of drugs that has transformed the treatment of type 2 diabetes and obesity. Under the new policy, Medicare’s reimbursement rates for these medications will align with the lowest prices paid in five high-income countries: Canada, Germany, France, Japan, and the UK. The policy, scheduled to take effect in November 2025, is designed to reduce out-of-pocket costs for seniors and expand access to medications that have demonstrated significant benefits in reducing complications such as heart disease, stroke, and kidney failure.

The announcement follows years of debate over the affordability of prescription drugs in the U.S., where prices for GLP-1 drugs have soared to over $1,000 per month. For comparison, the same medications cost as little as $300 per month in some of the countries included in the MFN framework. The policy’s architects argue that aligning U.S. prices with global benchmarks could save Medicare billions while improving health outcomes for millions of Americans.

However, the transition is not without risks. The Congressional Budget Office (CBO) has cautioned that the policy could increase Medicare spending if demand for GLP-1 drugs surges beyond projections. Additionally, pharmaceutical manufacturers have raised concerns about potential supply constraints and reduced investment in innovation, which could limit patient access to these critical therapies.

Why Public Health Officials Are Concerned

The stakes of this policy extend far beyond Medicare’s financial health. GLP-1 drugs represent a paradigm shift in the management of chronic diseases, offering benefits that extend beyond glycemic control. For patients with type 2 diabetes, these medications reduce the risk of cardiovascular events by up to 26%, according to findings from the SUSTAIN-6 trial published in The New England Journal of Medicine. For individuals with obesity, GLP-1 drugs like Wegovy and Zepbound have demonstrated sustained weight loss of 15% or more over 68 weeks, as reported in the STEP trials. These outcomes translate into fewer hospitalizations, lower healthcare costs, and improved quality of life.

Yet, the high cost of these medications has created a stark disparity in access. A 2023 study in JAMA Internal Medicine found that only 12% of Medicare beneficiaries with diabetes or obesity were able to afford GLP-1 drugs without financial assistance. The MFN policy aims to bridge this gap by making these treatments more affordable, but public health officials are closely monitoring several potential challenges:

• Medicare’s Financial Viability: GLP-1 drugs accounted for over $40 billion in Medicare Part D spending in 2023, according to data from the Centers for Medicare & Medicaid Services (CMS). While the MFN policy could reduce these costs, the savings may be offset by increased utilization. The CBO estimates that the policy could result in a net increase in Medicare spending of up to $5 billion over the next decade if demand exceeds expectations.
• Supply Chain and Accessibility: Pharmaceutical companies have warned that the MFN policy could discourage production or lead to supply shortages, particularly if manufacturers prioritize markets with higher profit margins. This risk is compounded by the global demand for GLP-1 drugs, which has already strained manufacturing capacity.
• Innovation and Investment: The pharmaceutical industry has expressed concerns that reduced revenue from U.S. sales could slow investment in research and development for next-generation GLP-1 drugs and related therapies. This could delay the introduction of new treatments or improvements to existing ones.

Public health advocates emphasize that the policy’s success hinges on balancing affordability with sustainability. If Medicare cannot achieve budget neutrality, the program’s long-term solvency could be jeopardized, potentially leading to cuts in other essential services.

Symptoms or Risk Factors

GLP-1 drugs are not associated with symptoms in the traditional sense, but their high cost and limited accessibility pose significant risks to patient health and well-being. For individuals who rely on these medications, the inability to afford them can lead to:

• Poorly controlled diabetes, increasing the risk of complications such as blindness, nerve damage, and kidney disease.
• Unmanaged obesity, which is linked to a higher incidence of cardiovascular disease, certain cancers, and reduced life expectancy.
• Financial strain, particularly for seniors on fixed incomes, who may face difficult choices between paying for medications or other essential needs.

The MFN policy aims to mitigate these risks by making GLP-1 drugs more affordable, but its effectiveness will depend on how well Medicare and insurers adapt to the new pricing structure.

Who May Be Affected

The MFN pricing policy will have a broad impact, affecting multiple stakeholders within the healthcare ecosystem:

• Medicare Beneficiaries: Approximately 65 million Americans rely on Medicare for healthcare coverage, including 28 million who have diabetes or obesity. For these individuals, the policy could mean the difference between accessing life-saving treatments and going without.
• Healthcare Providers: Clinicians who prescribe GLP-1 drugs will need to navigate changes in formularies, prior authorization requirements, and potential supply shortages. Providers may also face increased patient inquiries about coverage and affordability.
• Pharmaceutical Companies: Manufacturers of GLP-1 drugs, including Novo Nordisk, Eli Lilly, and others, will need to adjust their pricing strategies and production plans to comply with the MFN framework. The policy could reduce revenue from U.S. sales, potentially impacting profitability and investment in innovation.
• Insurance Providers: Medicare Part D plans and other insurers will need to update their formularies and reimbursement rates to align with the new pricing structure. This may require additional administrative resources and could lead to changes in patient access to specific medications.
• Taxpayers: As Medicare beneficiaries, taxpayers indirectly fund the program. The MFN policy’s success or failure could influence Medicare’s long-term financial health, which in turn affects federal spending and budget priorities.

The policy’s impact will vary depending on factors such as geographic location, socioeconomic status, and individual health needs. Rural communities, for example, may face greater challenges in accessing GLP-1 drugs due to limited pharmacy availability or transportation barriers.

Government or WHO Response

The White House’s MFN pricing policy is part of a broader effort to address the affordability of prescription drugs in the U.S. The policy aligns with the Biden administration’s commitment to lowering healthcare costs and improving access to essential medications. In a statement, the Department of Health and Human Services (HHS) emphasized that the policy is designed to ensure that Medicare beneficiaries receive the same value for their healthcare dollars as patients in other high-income countries.

The World Health Organization (WHO) has not issued a formal response to the U.S. policy, but the organization has long advocated for policies that reduce drug prices and improve access to essential medicines. In its Global Strategy on Public Health, Innovation and Intellectual Property, the WHO highlights the need for governments to implement pricing strategies that balance affordability with innovation.

The CBO has played a critical role in evaluating the potential impact of the MFN policy. In its 2024 report, the CBO projected that the policy could reduce Medicare spending on GLP-1 drugs by $30 billion over the next decade, but noted that the savings could be offset by increased utilization and other factors. The CBO’s analysis underscores the need for ongoing monitoring and adjustment to ensure the policy achieves its intended goals.

Prevention and Safety Guidance

While the MFN policy aims to improve access to GLP-1 drugs, patients and providers should take proactive steps to navigate the transition and mitigate potential risks:

• Review Your Coverage: Medicare beneficiaries should review their Part D plan’s formulary to determine which GLP-1 drugs are covered and whether prior authorization is required. Contact your insurer or a Medicare representative for detailed information about your specific plan.
• Plan Ahead for Supply:
• Advocate for Coverage: If your Medicare plan denies coverage for a GLP-1 drug, you have the right to appeal the decision. The MFN policy strengthens your case by demonstrating that the medication is available at a lower cost in other countries. Work with your healthcare provider to submit an appeal and provide supporting documentation.
• Explore Financial Assistance Programs: Many pharmaceutical companies offer patient assistance programs that provide free or discounted medications to individuals who qualify. Additionally, organizations such as the Patient Access Network (PAN) Foundation and the Diabetes Disaster Relief Coalition offer financial support for diabetes medications.
• Monitor for Shortages: Stay informed about potential supply constraints by checking updates from the FDA, CMS, and your medication’s manufacturer. If a shortage is announced, work with your healthcare provider to explore alternative treatments or strategies to manage your condition.
• Prioritize Adherence: If you are already taking a GLP-1 drug, do not stop or adjust your dosage without consulting your healthcare provider. Abruptly discontinuing these medications can lead to worsening of diabetes or weight regain. If you experience difficulties obtaining your medication, discuss alternative options with your provider.

What Readers Should Know

The MFN pricing policy for GLP-1 drugs represents a bold experiment in U.S. drug pricing, with the potential to reshape access to life-saving treatments for millions of Americans. However, its success is not guaranteed. Patients, providers, and policymakers must remain vigilant to ensure that the policy achieves its intended goals without unintended consequences.

For patients, the most immediate concern is access. The MFN policy could make GLP-1 drugs more affordable, but only if Medicare and insurers implement the changes effectively. Patients should proactively engage with their healthcare providers and insurers to understand how the policy affects their coverage and explore all available options for financial assistance.

For providers, the policy introduces new challenges in prescribing and managing GLP-1 drugs. Clinicians may need to spend additional time navigating formularies, prior authorization requirements, and supply constraints. Providers should stay informed about updates from CMS, the FDA, and professional organizations such as the American Diabetes Association (ADA) and the Obesity Medicine Association (OMA).

For policymakers, the MFN policy underscores the need for a balanced approach to drug pricing that prioritizes both affordability and innovation. The CBO’s analysis highlights the importance of ongoing monitoring and adjustment to ensure that the policy achieves its intended savings without compromising patient access or pharmaceutical investment.

The next 12 months will be critical in determining the policy’s success. Medicare’s financial health, patient access to GLP-1 drugs, and the pharmaceutical industry’s response will all shape the outcome. One thing is clear: the era of unchecked drug pricing in the U.S. is coming to an end, and the decisions made in the coming months will have lasting implications for patients, providers, and the healthcare system as a whole.

Key Takeaways

• The White House’s MFN pricing policy for GLP-1 drugs aims to align U.S. Medicare reimbursement rates with the lowest prices paid in Canada, Germany, France, Japan, and the UK, effective November 2025.
• GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have demonstrated significant benefits in reducing complications from diabetes and obesity, but their high cost has limited access for many Americans.
• The policy could reduce Medicare spending on GLP-1 drugs by $30 billion over the next decade, according to the Congressional Budget Office, but increased utilization may offset some of these savings.
• Pharmaceutical companies have warned of potential supply shortages and reduced investment in innovation due to the MFN policy, raising concerns about long-term access to these critical medications.
• Patients should proactively review their Medicare Part D coverage, explore financial assistance programs, and advocate for coverage if denied, while providers should stay informed about policy updates and alternative treatment options.

Frequently Asked Questions

How will the MFN pricing policy affect the cost of GLP-1 drugs for Medicare beneficiaries?

Under the MFN policy, Medicare’s reimbursement rates for GLP-1 drugs will align with the lowest prices paid in Canada, Germany, France, Japan, or the UK. For example, the cost of Ozempic could drop from over $1,000 per month to as low as $300 per month. However, the actual out-of-pocket cost for beneficiaries will depend on their specific Medicare Part D plan, deductibles, and copayments.

What are the potential risks of the MFN policy for Medicare beneficiaries?

The primary risks include supply shortages, changes in formulary coverage, and increased prior authorization requirements. If pharmaceutical companies reduce production due to lower profit margins, patients may face difficulties obtaining their medications. Additionally, some Medicare Part D plans may adjust their formularies to exclude certain GLP-1 drugs, limiting patient choice.

How can patients appeal a denial of coverage for a GLP-1 drug under the new policy?

If a Medicare Part D plan denies coverage for a GLP-1 drug, patients have the right to appeal the decision. The process typically involves submitting a written appeal to the plan, providing supporting documentation from a healthcare provider, and requesting a redetermination. Patients can also contact their State Health Insurance Assistance Program (SHIP) for guidance and support.

What financial assistance programs are available for patients who cannot afford GLP-1 drugs?

Several organizations offer financial assistance for GLP-1 drugs, including the Patient Access Network (PAN) Foundation, the Diabetes Disaster Relief Coalition, and patient assistance programs run by pharmaceutical companies like Novo Nordisk and Eli Lilly. Patients should contact their healthcare provider or a patient advocacy organization to explore eligibility and application processes.

Will the MFN policy impact the availability of GLP-1 drugs in the future?

The long-term impact on availability will depend on how pharmaceutical companies respond to the MFN policy. If manufacturers reduce production or investment in innovation due to lower revenue from U.S. sales, there could be supply constraints or delays in the introduction of new GLP-1 drugs. Policymakers and patient advocates are closely monitoring these developments to ensure continued access to these critical medications.

---

Medical Review: MedSense Editorial Board